Searched for
PHARMA INNOVATION IN INDIA
Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovationThermo Fisher Scientific is amplifying its investment footprint in India, driven by the strong anticipated growth in the biosimilars and in...- End dependence days: What India should and should not buildCurrent government procurement policies can obstruct innovation, often favouring established firms. Furthermore, major Indian corporations ...
- Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEOGland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to h...
- Q1 Earnings Scorecard: Strong demand drives revenue, input costs hit profitsSustained market demand led to impressive revenue growth in the automotive and consumer goods sectors. In contrast, while the banking secto...
- Medical devices are not pharma products, companies say while opposing Draft BillIndia’s medical device industry and healthcare groups have opposed the draft Drugs, Medical Devices and Cosmetics Bill, 2026, arguing that ...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- World Bank's IFC, HDFC AMC invest in Molbio Diagnostics' Rs 281 crore IPO anchor roundMolbio Diagnostics raised Rs 281 crore from anchor investors, including World Bank Group's IFC and HDFC Mutual Fund, ahead of its Rs 940 cr...
- Lupin Q1 PAT rises 16 pc at Rs 1,417 crLupin Ltd has reported a remarkable sixteen percent surge in profit after tax for the first quarter, showcasing their continued success. Th...
- India Inc goes on a global shopping spree with a new wishlistIndian companies are increasingly pursuing strategic overseas acquisitions. They now focus on acquiring capabilities and technology rather ...
- Japan's Takeda bets on dengue vax to reshape India playbookTakeda Pharmaceutical's new dengue vaccine Qdenga received approval in India. The vaccine is expected to launch commercially in early 2027....
- ET Health Conclave 2026: Healthcare leaders reimagine the future of medicine through innovation, prevention and technologyThe ET Health Conclave 2026 celebrated healthcare professionals and institutions. Leaders shared insights on healthcare infrastructure and ...
- MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...
- Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...
- Technology sector funds dominate July returns; 9 mutual funds deliver over 10% gains. Should investors ride the rally?Technology sector mutual funds achieved substantial gains during July. HDFC Technology Fund led with a remarkable 16.91% return for investo...
- ET Family Business Awards: Serum Institute, Mankind, Varun Beverages among winners in the limelightSeveral Indian family businesses received awards for their significant contributions. Serum Institute of India was honored for philanthropi...
- As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent PharmaceuticalsTorrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
- Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives valueIndia's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...
Load More
